HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

Abstract
Clinical studies using the microtubule-targeting agent 2-methoxyestradiol (2ME2; Panzem) in cancer patients show that treatment is associated with clinical benefit, including prolonged stable disease, complete and partial responses, and an excellent safety profile. Studies have shown that 2ME2 is metabolized by conjugation at positions 3 and 17 and oxidation at position 17. To define structure-activity relationships for these positions of 2ME2 and to generate metabolically stable analogues with improved anti-tubulin properties, a series of analogues was generated and three lead analogues were selected, ENMD-1198, ENMD-1200, and ENMD-1237. These molecules showed improved metabolic stability with >65% remaining after 2-h incubation with hepatocytes. Pharmacokinetic studies showed that oral administration of the compounds resulted in increased plasma levels compared with 2ME2. All three analogues bind the colchicine binding site of tubulin, induce G(2)-M cell cycle arrest and apoptosis, and reduce hypoxia-inducible factor-1alpha levels. ENMD-1198 and ENMD-1200 showed improved in vitro antiproliferative activities. Significant reductions in tumor volumes compared with vehicle-treated mice were observed in an orthotopic breast carcinoma (MDA-MB-231) xenograft model following daily oral treatment with all compounds (ANOVA, P < 0.05). Significantly improved median survival time was observed with ENMD-1198 and ENMD-1237 (200 mg/kg/d) in a Lewis lung carcinoma metastatic model (P < 0.05). In both tumor models, the high-dose group of ENMD-1198 showed antitumor activity equivalent to that of cyclophosphamide. ENMD-1198 was selected as the lead molecule in this analogue series and is currently in a phase I clinical trial in patients with refractory solid tumors.
AuthorsTheresa M LaVallee, Patricia A Burke, Glenn M Swartz, Ernest Hamel, Gregory E Agoston, Jamshed Shah, Lita Suwandi, Art D Hanson, William E Fogler, Carolyn F Sidor, Anthony M Treston
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 7 Issue 6 Pg. 1472-82 (Jun 2008) ISSN: 1535-7163 [Print] United States
PMID18566218 (Publication Type: Journal Article)
Chemical References
  • 2-methoxyoestra-1,3,5(10),16-tetraene-3-carboxamide
  • Antineoplastic Agents
  • Estrenes
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Tubulin
  • Tubulin Modulators
  • Estradiol
  • 2-Methoxyestradiol
  • Colchicine
Topics
  • 2-Methoxyestradiol
  • Administration, Oral
  • Animals
  • Antineoplastic Agents (administration & dosage, chemistry, pharmacokinetics, pharmacology)
  • Apoptosis (drug effects)
  • Binding, Competitive (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Colchicine (pharmacology)
  • Drug Screening Assays, Antitumor
  • Estradiol (analogs & derivatives, chemistry)
  • Estrenes (administration & dosage, chemistry, pharmacokinetics, pharmacology)
  • G2 Phase (drug effects)
  • Hepatocytes (drug effects, metabolism)
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit (metabolism)
  • Inhibitory Concentration 50
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Microtubules (drug effects)
  • Mitosis (drug effects)
  • Rats
  • Survival Analysis
  • Tubulin (metabolism)
  • Tubulin Modulators (administration & dosage, chemistry, pharmacokinetics, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: